For example, a recent report showed that YAP/TAZ activities are controlled by the mevalonate pathway[117], suggesting that FDA-approved cholesterol biosynthesis inhibitors, such as Statins, have the potential to target YAP/TAZ in malignant cancer cells. Here, YAP1 is linked to cancer.